Virpax Pharmaceuticals, Inc. (VRPX) Social Stream



Virpax Pharmaceuticals, Inc. (VRPX): $3.72

0.05 (-1.33%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

F

Add VRPX to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#369 of 422

in industry

VIRPAX PHARMACEUTICALS INC (VRPX) Price Targets From Analysts

Use the tables below to see what analysts covering VIRPAX PHARMACEUTICALS INC think about its future price and what recommendations they have for investors and traders.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2022-07-01 1 $4 $4 $4 $0.312 1182.05%
2023-10-13 1 $2 $2 $2 $0.312 541.03%
NA 1 $NA $NA $NA $0.312 NA%

Price Target Last Issued October 13, 2023

VRPX Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1 1 0 0 0 0 1

The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.

  • In the context of all US stocks, VIRPAX PHARMACEUTICALS INC's number of analysts covering the stock is higher than practically none of them.
  • In terms of how VIRPAX PHARMACEUTICALS INC fares relative to all US stocks, note that its variance in analysts' estimates is lower than almost 100% of that group.
  • In terms of how VIRPAX PHARMACEUTICALS INC fares relative to Healthcare stocks, note that its average analyst price target is greater than 5.48% of that group.
  • VIRPAX PHARMACEUTICALS INC's upside potential (average analyst target price relative to current price) is greater than 175.78% of Healthcare stocks.

In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to VIRPAX PHARMACEUTICALS INC are LBPH, RPHM, and ANEB.

What is the outlook for VRPX? Use POWR Ratings for clearer insight into price direction.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!